Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O43909

UPID:
EXTL3_HUMAN

ALTERNATIVE NAMES:
EXT-related protein 1; Glucuronyl-galactosyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase; Hereditary multiple exostoses gene isolog; Multiple exostosis-like protein 3; Putative tumor suppressor protein EXTL3

ALTERNATIVE UPACC:
O43909; D3DST8; O00225; Q53XT3

BACKGROUND:
The protein Exostosin-like 3, or EXTL3, is a glycosyltransferase essential for heparan sulfate proteoglycans (HSPGs) formation, impacting skeletal development and hematopoiesis. It acts as a receptor for REG proteins, influencing keratinocyte proliferation, skin inflammation, and glucose tolerance. EXTL3's expression in microglia and its role in inhibiting the kynurenine pathway to prevent endotoxic death further underscore its biological significance.

THERAPEUTIC SIGNIFICANCE:
Given EXTL3's critical role in immunoskeletal dysplasia with neurodevelopmental abnormalities, targeting this protein could offer new therapeutic avenues. The exploration of EXTL3 functions opens doors to potential strategies for treating skeletal and neurodevelopmental disorders, as well as immunodeficiencies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.